A quantitative atlas of histone modification signatures from human cancer cells

Table 2 Comparison between several observed histone PTM levels in this study and other studies (Chervona and Costa 2012)

Histone modification	Observation in this study	Observation in other studies
H3K4me3	Elevated in HCT116 colon line	Elevated SMYD3 HMT levels in colorectal carcinomas [31]
H3K9me3	Reduced in NB4 and HL60 leukemia lines	Reduced in promoter regions of acute myeloid leukemia patients [32]
H3K9me3 and H3K9me3K14ac	Elevated in MDA-MB231 and MCF7 breast lines	Elevated in circulating nucleosomes of breast cancer patients [33]
H3K18acK23un	Reduced in 293 kidney and H1229 lung lines	Reduced in poor prognosis kidney and lung cancer patients [34]
H3K27me3	Elevated in SAOS bone line	Elevated EZH2 HMT expression in osteosarcomas [35]
H3K27me3	Elevated in MDA-MB231 and MCF7 breast lines	Elevated EZH2 HMT expression in breast cancer [19]
H3K36me1 and H3K36me2	Elevated in HL60 leukemia line	Elevated recruitment of NSD1 HMT translocation in acute myeloid leukemias [36]
H4K16ac	Reduced in MDA-MB231 and MCF7 breast lines	Reduced in patient breast tumors [28]
H4K20me2	Reduced in PC3 prostate line	Reduced in metastatic and castration-resistant prostate cancer [37]
H4K20me3	Reduced in H1229 lung line	Reduced in lung carcinoma progression [38]

ISSN: 1756-8935